Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969352110> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2969352110 abstract "Abstract INTRODUCTION Surgery is an effective treatment for many pharmacoresistant temporal lobe epilepsy patients, but incurs considerable cost. It is unknown whether surgery and surgical evaluation are cost-effective strategies in the United States. We aim to evaluate whether 1) surgery is cost-effective for patients who have been deemed surgical candidates when compared to continued medical management, 2) surgical evaluation is cost-effective for patients who have drug-resistant temporal epilepsy and may or may not ultimately be deemed surgical candidates METHODS We use a Monte Carlo simulation method to assess the cost-effectiveness of surgery and surgical evaluation over a lifetime horizon. Patients transition between two health states (‘seizure free’ and ‘having seizures’) as part of a Markov process, based on literature estimates. We adopt both healthcare and societal perspectives, including direct healthcare costs and indirect costs such as lost earnings by patients and care providers. We estimate variability of model predictions using probabilistic and deterministic sensitivity analyses. RESULTS 1) Epilepsy surgery is cost effective in surgically eligible patients by virtue of being cost saving and more effective than medical management in the long run, with 95% of 10 000 Monte Carlo simulations favoring surgery. From a societal perspective, surgery becomes cost effective within 3 yr. At 5 yr, surgery has an incremental cost-effectiveness ratio (ICER) of $31,600, which is significantly below the societal willingness-to-pay (∼ $100,000/quality-adjusted life years (QALY)) and comparable to hip/knee arthroplasty. 2) Surgical evaluation is cost-effective in pharmacoresistant patients even if the probability of being deemed a surgical candidate is low (5%-10%). Even if the probability of surgical eligibility is only 10%, surgical referral has an ICER of $96,000/QALY, which is below societal willingness-to-pay. CONCLUSION Epilepsy surgery and surgical evaluation are both cost-effective strategies in the United States. Pharmacoresistant temporal lobe epilepsy patients should be referred for surgical evaluation without hesitation on cost-effectiveness grounds." @default.
- W2969352110 created "2019-08-29" @default.
- W2969352110 creator A5001332221 @default.
- W2969352110 creator A5014134631 @default.
- W2969352110 creator A5017972156 @default.
- W2969352110 creator A5018120847 @default.
- W2969352110 creator A5031579768 @default.
- W2969352110 creator A5054374857 @default.
- W2969352110 date "2019-08-20" @default.
- W2969352110 modified "2023-10-18" @default.
- W2969352110 title "The Cost-Effectiveness of Epilepsy Surgery and Surgical Evaluation in the United States" @default.
- W2969352110 doi "https://doi.org/10.1093/neuros/nyz310_165" @default.
- W2969352110 hasPublicationYear "2019" @default.
- W2969352110 type Work @default.
- W2969352110 sameAs 2969352110 @default.
- W2969352110 citedByCount "2" @default.
- W2969352110 countsByYear W29693521102020 @default.
- W2969352110 crossrefType "journal-article" @default.
- W2969352110 hasAuthorship W2969352110A5001332221 @default.
- W2969352110 hasAuthorship W2969352110A5014134631 @default.
- W2969352110 hasAuthorship W2969352110A5017972156 @default.
- W2969352110 hasAuthorship W2969352110A5018120847 @default.
- W2969352110 hasAuthorship W2969352110A5031579768 @default.
- W2969352110 hasAuthorship W2969352110A5054374857 @default.
- W2969352110 hasBestOaLocation W29693521101 @default.
- W2969352110 hasConcept C112930515 @default.
- W2969352110 hasConcept C118552586 @default.
- W2969352110 hasConcept C141071460 @default.
- W2969352110 hasConcept C159110408 @default.
- W2969352110 hasConcept C160735492 @default.
- W2969352110 hasConcept C162324750 @default.
- W2969352110 hasConcept C2778186239 @default.
- W2969352110 hasConcept C2779951463 @default.
- W2969352110 hasConcept C2780803581 @default.
- W2969352110 hasConcept C3019080777 @default.
- W2969352110 hasConcept C50522688 @default.
- W2969352110 hasConcept C71924100 @default.
- W2969352110 hasConceptScore W2969352110C112930515 @default.
- W2969352110 hasConceptScore W2969352110C118552586 @default.
- W2969352110 hasConceptScore W2969352110C141071460 @default.
- W2969352110 hasConceptScore W2969352110C159110408 @default.
- W2969352110 hasConceptScore W2969352110C160735492 @default.
- W2969352110 hasConceptScore W2969352110C162324750 @default.
- W2969352110 hasConceptScore W2969352110C2778186239 @default.
- W2969352110 hasConceptScore W2969352110C2779951463 @default.
- W2969352110 hasConceptScore W2969352110C2780803581 @default.
- W2969352110 hasConceptScore W2969352110C3019080777 @default.
- W2969352110 hasConceptScore W2969352110C50522688 @default.
- W2969352110 hasConceptScore W2969352110C71924100 @default.
- W2969352110 hasIssue "Supplement_1" @default.
- W2969352110 hasLocation W29693521101 @default.
- W2969352110 hasOpenAccess W2969352110 @default.
- W2969352110 hasPrimaryLocation W29693521101 @default.
- W2969352110 hasRelatedWork W1968361987 @default.
- W2969352110 hasRelatedWork W1977757989 @default.
- W2969352110 hasRelatedWork W2035694213 @default.
- W2969352110 hasRelatedWork W2045045972 @default.
- W2969352110 hasRelatedWork W2053267038 @default.
- W2969352110 hasRelatedWork W2083316084 @default.
- W2969352110 hasRelatedWork W2093661366 @default.
- W2969352110 hasRelatedWork W2751708244 @default.
- W2969352110 hasRelatedWork W2912302657 @default.
- W2969352110 hasRelatedWork W2947357553 @default.
- W2969352110 hasVolume "66" @default.
- W2969352110 isParatext "false" @default.
- W2969352110 isRetracted "false" @default.
- W2969352110 magId "2969352110" @default.
- W2969352110 workType "article" @default.